Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: URN009
MIFTS: 59

Urinary System Disease

Categories: Nephrological diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Urinary System Disease

About this section

MalaCards integrated aliases for Urinary System Disease:

Name: Urinary System Disease 12 15 17
Abnormality of the Urinary System 30 6
Congenital Malformation of the Urinary System 74
Non-Neoplastic Urinary System Disorder 74
Non-Neoplastic Urinary Tract Disease 12
Urinary Tract Diseases 56
Urinary Tract Disease 12
Urinary Tract Anomaly 56
Urologic Diseases 74

Classifications:

MalaCards categories:
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:18
NCIt 51 C27599
Sources

Summaries for Urinary System Disease

About this section
Disease Ontology : 12 A disease of anatomical entity that is located in kidney, ureter, bladder and urethra.

MalaCards based summary : Urinary System Disease, also known as abnormality of the urinary system, is related to bladder disease and kidney disease, and has symptoms including dysuria, polyuria and urgency of micturition. An important gene associated with Urinary System Disease is B2M (Beta-2-Microglobulin), and among its related pathways/superpathways are Primary Focal Segmental Glomerulosclerosis FSGS and Overview of nanoparticle effects. The drugs leucovorin and Ofloxacin have been mentioned in the context of this disorder. Affiliated tissues include kidney, testes and endothelial, and related phenotypes are no effect and cardiovascular system

Wikipedia : 77 The urinary system, also known as the renal system or urinary tract, consists of the kidneys, ureters,... more...

Sources

Related Diseases for Urinary System Disease

About this section

Diseases related to Urinary System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 139)
# Related Disease Score Top Affiliating Genes
1 bladder disease 32.2 CRP KLK3 KRT20
2 kidney disease 31.5 ACE ALB B2M CRP CST3 EPO
3 vesicoureteral reflux 1 30.8 NAGLU REN UMOD
4 cystitis 30.7 CRP KRT20 UMOD
5 acute cystitis 30.7 ALB CRP KLK3
6 acute pyelonephritis 30.6 ALB CRP NAGLU
7 pyelonephritis 30.5 ACE ALB CRP NAGLU UMOD
8 pyuria 30.5 ALB CRP
9 chronic kidney failure 29.8 ACE ALB B2M CRP CST3 EPO
10 congenital anomalies of kidney and urinary tract 2 11.6
11 congenital anomalies of kidney and urinary tract 1 11.3
12 exstrophy of bladder 11.1
13 chromosome 6q11-q14 deletion syndrome 11.1
14 alpha-thalassemia 10.9
15 cakut 10.9
16 urethral syndrome 10.9
17 bacteriuria 10.9
18 ureteral disease 10.9
19 lower urinary tract calculus 10.9
20 cystic kidney disease 10.6 ALB B2M UMOD
21 loeffler syndrome 10.6 ACE ALB
22 hypoaldosteronism 10.6 ACE REN
23 uremic neuropathy 10.6 B2M EPO PTH
24 hypertensive nephropathy 10.6 ACE ALB NAGLU
25 anuria 10.6 ACE ALB REN
26 hypertensive encephalopathy 10.6 ACE EPO REN
27 renal artery disease 10.6 ACE EPO REN
28 non-secretory myeloma 10.6 ALB B2M FN1
29 prostatic acinar adenocarcinoma 10.6 KLK3 KRT20 WT1
30 microvascular complications of diabetes 3 10.6 ACE ALB NPHS1
31 pyelitis 10.6 B2M CRP REN
32 hyperparathyroidism 10.6 EPO FGF23 PTH
33 renal tuberculosis 10.6 B2M CRP REN
34 orthostatic proteinuria 10.6 ACE ALB B2M REN
35 kidney hypertrophy 10.6 ALB NPHS1 NPHS2
36 atrial septal defect 3 10.6 NPHS1 NPHS2 REN
37 hydronephrosis 10.6 ALB B2M NAGLU
38 renal artery obstruction 10.6 ACE REN
39 angiokeratoma of fordyce 10.6 ACE WT1
40 hemorrhagic fever with renal syndrome 10.6 ALB B2M CRP
41 nephrotic syndrome, type 6 10.6 NPHS1 NPHS2 WT1
42 immunodeficiency 43 10.6 ALB B2M
43 pure autonomic failure 10.6 ACE EPO REN
44 acute kidney failure 10.6 ALB B2M CST3 REN
45 seminal vesicle adenocarcinoma 10.6 KLK3 KRT20
46 familial idiopathic steroid-resistant nephrotic syndrome with focal segmental hyalinosis 10.6 NPHS1 NPHS2 WT1
47 familial nephrotic syndrome 10.6 NPHS1 NPHS2 WT1
48 hepatorenal syndrome 10.6 ACE ALB CST3 REN
49 parathyroid gland disease 10.6 ALB FGF23 PTH
50 granulomatous angiitis 10.6 ACE CRP CST3

Graphical network of the top 20 diseases related to Urinary System Disease:



Diseases related to Urinary System Disease
Sources

Symptoms & Phenotypes for Urinary System Disease

About this section

UMLS symptoms related to Urinary System Disease:


dysuria, polyuria, urgency of micturition, other and unspecified genitourinary symptoms, renal colic, pain in urethra, uti symptoms, urethral burning on micturition, loin pain, ureteral pain, flank tenderness, difficulty passing urine, urinary tenesmus, burning urination, bladder discomfort, renal pain, urologic problem

GenomeRNAi Phenotypes related to Urinary System Disease according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 ACE ALB B2M CCR6 CRP CST3

MGI Mouse Phenotypes related to Urinary System Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.29 ACE B2M CRP CST3 EPO FGF23
2 homeostasis/metabolism MP:0005376 10.28 ACE ALB B2M CCR6 CRP CST3
3 growth/size/body region MP:0005378 10.2 ACE B2M FGF23 FN1 NAGLU NPHS2
4 immune system MP:0005387 10.18 ACE B2M CCR6 CRP EPO FGF23
5 hematopoietic system MP:0005397 10.17 ACE B2M CCR6 EPO FGF23 FN1
6 mortality/aging MP:0010768 10.1 ACE ALB B2M CST3 EPO FGF23
7 liver/biliary system MP:0005370 9.87 ACE ALB B2M EPO FN1 NAGLU
8 muscle MP:0005369 9.7 ALB CST3 EPO FN1 REN SIX1
9 neoplasm MP:0002006 9.43 ACE ALB B2M CST3 FN1 WT1
10 renal/urinary system MP:0005367 9.32 ACE ALB FGF23 NAGLU NPHS1 NPHS2
Sources

Drugs & Therapeutics for Urinary System Disease

About this section

Drugs for Urinary System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1615)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
2
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 82419-36-1 4583
3
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 100986-85-4 149096
4 Cranberry Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
5
Nitrofurantoin Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 67-20-9 5353830
6
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 738-70-5 5578
7
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 104987-11-3 6473866 445643 439492
8
Pitavastatin Approved Phase 4,Phase 1 147511-69-1, 147526-32-7 5282452 6366718
9
Losartan Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 114798-26-4 3961
10
Irbesartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 138402-11-6 3749
11
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 11128-99-7, 68521-88-0, 4474-91-3 172198
12
Pentoxifylline Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 6493-05-6 4740
13
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 137862-53-4 60846
14
Candesartan cilexetil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 145040-37-5 2540
15
Olmesartan Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 144689-24-7, 144689-63-4 158781 130881
16
Telmisartan Approved, Investigational Phase 4,Phase 3,Not Applicable 144701-48-4 65999
17
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 53123-88-9 46835353 5284616 6436030
18
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 159351-69-6 70789204 6442177
19
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
20
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 616-91-1 12035
21
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
22
alemtuzumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 216503-57-0
23
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75847-73-3 40466924 5362032
24
Enalaprilat Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76420-72-9 6917719
25
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7439-89-6, 15438-31-0 27284 23925
26
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 76-42-6 5284603
27
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
28
Fosfomycin Approved Phase 4,Phase 3,Phase 2,Not Applicable 23155-02-4 446987
29
Piperacillin Approved Phase 4,Phase 2,Phase 3 66258-76-2 43672
30
Sulbactam Approved Phase 4,Phase 3,Phase 2,Phase 1 68373-14-8
31
carbamide peroxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-43-6
32
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 46507594 772
33
Dalteparin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6
34
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 9004-61-9 53477741
35
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 54-31-9 3440
36
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-93-5 3639
37
Spironolactone Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1952-01-7, 52-01-7 5833
38
Amiodarone Approved, Investigational Phase 4,Not Applicable 1951-25-3 2157
39
Warfarin Approved Phase 4,Phase 2,Phase 1 81-81-2 54678486 6691
40
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 2,Not Applicable 128-13-2 31401
41
Digoxin Approved Phase 4 20830-75-5 2724385 30322
42
Lithium carbonate Approved Phase 4,Phase 2 554-13-2
43
Pirfenidone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53179-13-8 40632
44
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
45
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
46
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 113775-47-6 5311068 68602
47
acetic acid Approved Phase 4,Not Applicable 64-19-7 176
48
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
49
Nifedipine Approved Phase 4,Phase 3,Phase 2,Phase 1 21829-25-4 4485
50
Progesterone Approved, Vet_approved Phase 4,Not Applicable 57-83-0 5994

Interventional clinical trials:

(show top 50) (show all 10001)
# Name Status NCT ID Phase Drugs
1 Folic Acid for Prevention of Contrast Induced Nephropathy Unknown status NCT02444013 Phase 4 Folic acid;Placebo
2 Levofloxacin as an Empirical Therapy in Patients With Complicated Urinary Tract Infections Unknown status NCT03160807 Phase 4 Levofloxacin;Levofloxacin
3 Cranberry for the Prevention of Urinary Tract Infections Unknown status NCT02454309 Phase 4
4 Effects of Antibiotic Prophylaxis on Recurrent UTI in Children Unknown status NCT02357758 Phase 4 Antibiotic Prophylaxis
5 Practical Use of Advagraf de Novo After Kidney Transplantation According to Recipient Genetic Polymorphism Unknown status NCT02311010 Phase 4 Advagraf
6 The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females Unknown status NCT02094703 Phase 4 Levofloxacin;Solifenacin succinate;Placebo (for Solifenacin succinate)
7 Gentamicin Bladder Instillation Trial Unknown status NCT01884467 Phase 4 Gentamicin;Placebo
8 Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction Unknown status NCT01871792 Phase 4 Pitavastatin;Placebo
9 Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD) Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
10 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4 Kremezin
11 Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients Unknown status NCT00999258 Phase 4 sirolimus
12 Prevention of Contrast-Induced Nephropathy in Diabetic Patients With Undergoing Coronary Angiography Unknown status NCT00950079 Phase 4 Sodium bicarbonate;saline
13 Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy Unknown status NCT00939913 Phase 4 intravenous NAC;Placebo
14 Low Dose Estriol With Lactobacilli Treatment for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women Unknown status NCT00900653 Phase 4 Gynoflor E (low dose estriol with lactobacillus)
15 Safe Renal Function In Long Term Heart Transplanted Patients Unknown status NCT00505102 Phase 4 Everolimus
16 Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion Unknown status NCT00443508 Phase 4 adding Certican to therapy;reducing Tacrolimus
17 Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA) Unknown status NCT00290069 Phase 4 Tacrolimus;Rapamycin
18 Comparison of Alemtuzumab/Tacrolimus Versus Interleukin-2 Receptor (IL-2R) Monoclonal Antibody (MoAb)/Tacrolimus/Mycophenolate in Kidney Transplantation Unknown status NCT00246129 Phase 4 Alemtuzumab;Daclizumab
19 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril;candesartan and enalapril;candesartan and enalapril
20 Intravenous Iron in Patients With Anemia of Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
21 Evaluation of the Effectiveness of Antibiotic Prophylaxis in Children With a Previous Urinary Tract Infection Unknown status NCT00156546 Phase 4 antibiotic to reduce the recurrence of infection
22 Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement Unknown status NCT03121053 Phase 4 sodium bicarbonate;hypotone saline
23 Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease Unknown status NCT02885857 Phase 4 Shenyan Kangfu Tablet
24 Opioids in Chronic Kidney Disease Patients Undergoing Hemodialysis Unknown status NCT02452437 Phase 4 Oxycodone
25 Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease Unknown status NCT02299310 Phase 4 Valsartan;Perindopril
26 Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Unknown status NCT02231138 Phase 4 Abelmoschus manihot (AM)
27 Study Comparing Nitrofurantoin to Fosfomycin for Acute Urinary Tract Infection in Women Unknown status NCT01966653 Phase 4 nitrofurantoin;fosfomycin
28 Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection Unknown status NCT01897831 Phase 4 xin te mie
29 Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection Unknown status NCT01760109 Phase 4 Piperacillin Sodium and Sulbactam Sodium
30 Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2 Unknown status NCT01561222 Phase 4 Calcitriol;placebo
31 BIP Foley in Prevention of CAUTI at Rehab Station Unknown status NCT02808000 Phase 4
32 Enhancing Dialysis Adequacy: Effects of Intradialytic Exercise Unknown status NCT01481688 Phase 4
33 Minimizing Contrast Utilization With IVUS Guidance in Coronary Angioplasty to Avoid Acute Nephropathy Unknown status NCT02743156 Phase 4
34 A New Anticoagulation Method Using Dalteparin in Quotidian and Nocturnal Home Hemodialysis Patients Unknown status NCT02607111 Phase 4 Dalteparin
35 Thymoglobulin Induction Therapy in Kidney Transplantation (6mg/kg vs 4mg/kg) Unknown status NCT02447822 Phase 4 Thymoglobulin
36 The Prevention of Contrast Induced Nephropathy by Sarpogrelate in Patients With Chronic Kidney Disease Unknown status NCT01165567 Phase 4 sarpogrelate
37 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease Unknown status NCT01155128 Phase 4
38 Renal Effects of Meditarranean Diet and Low-protein Diet With Ketoacids on Physiological Intestinal Mibrobiota in CKD Unknown status NCT02302287 Phase 4
39 A Prospective Study Comparing the Success Rate of Injection of (DefluxR) Versus (VantrisR) for VUR in Children Unknown status NCT02271035 Phase 4 Deflux;Vantris
40 The Impact of Antimicrobial Treatment for Asymptomatic Bacteriuria in Renal Transplant Patients Unknown status NCT02113774 Phase 4
41 Clinical Trial to Compare Effectiveness of Diuretics in Hemodialysis Patients With Residual Renal Function Unknown status NCT01977430 Phase 4 Hydrochlorothiazide and furosemide
42 Effect of 3g Versus 2 g MMF in Combination With Tacrolimus on Progression of Renal Allograft Interstitial Fibrosis Unknown status NCT01860183 Phase 4 Mycophenolate mofetil
43 Efficacy and Safety of a Covered Self-expandable Dual-layered Metallic Mesh Stent (UVENTA) in Ureteral Obstruction Unknown status NCT01788865 Phase 4
44 Inspiratory Muscle Training in Patients With End Stage Renal Failure Unknown status NCT01347775 Phase 4
45 Keto-/Amino Acid Supplemented Low Protein Diet in Patients With Chronic Kidney Disease Unknown status NCT00364884 Phase 4 ketoaminoacid
46 Effects of Spironolactone in Dialysis Unknown status NCT01128101 Phase 4 Spironolactone
47 The Canadian Prevention of Renal and Cardiovascular Endpoints Trial Unknown status NCT00231803 Phase 4
48 Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure Unknown status NCT00716001 Phase 4 N-acetylcysteine
49 The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement. Unknown status NCT02710747 Phase 4
50 Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa Unknown status NCT02648126 Phase 4

Search NIH Clinical Center for Urinary System Disease

Sources

Genetic Tests for Urinary System Disease

About this section

Genetic tests related to Urinary System Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Urinary System 30
Sources

Anatomical Context for Urinary System Disease

About this section

MalaCards organs/tissues related to Urinary System Disease:

42
Kidney, Testes, Endothelial, Spinal Cord, Brain, T Cells, Neutrophil

The Foundational Model of Anatomy Ontology organs/tissues related to Urinary System Disease:

20
Kidney
Sources

Publications for Urinary System Disease

About this section

Articles related to Urinary System Disease:

# Title Authors Year
1
Chlamydia and male lower urinary tract diseases. ( 23550267 )
2013
2
Epidemiologic approach for early detection and control of renal and urinary tract diseases in rural populations. ( 17580586 )
2007
3
N-Glycans carried by Tamm-Horsfall glycoprotein have a crucial role in the defense against urinary tract diseases. ( 16622944 )
2005
4
[Implications of beta 2-microglobulin in the detection of associated urinary tract diseases in patients with infiltrative pulmonary tuberculosis]. ( 12577571 )
2002
5
Expression of platelet-derived endothelial cell growth factor and its potential role in up-regulation of angiogenesis in scarred kidneys secondary to urinary tract diseases. ( 10550316 )
1999
6
Urinary beta-HCG in benign and malignant urinary tract diseases. ( 7542189 )
1995
7
Natural history of peptic ulcer disease in Poland. Part X. Peptic ulcer disease and urinary tract diseases and diabetes. ( 2132430 )
1990
8
A population study on renal and urinary tract diseases. 3. A diagnostic dilemma: occurrence of pyuria and bacteriuria in conventional and clean-voided midstream specimens and suprapublic urine. ( 4589795 )
1973
9
A population study on renal and urinary tract diseases. II. Urinary deposits, bacteriuria and ESR on screening and medical examination of selected cases. ( 4773454 )
1973
Sources

Variations for Urinary System Disease

About this section

ClinVar genetic disease variations for Urinary System Disease:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 46;X;t(Y;3)(p11.2;p12.3)dn Translocation Likely pathogenic
2 CHD1L NM_004284.6(CHD1L): c.234C> T (p.Thr78=) single nucleotide variant Uncertain significance GRCh38 Chromosome 1, 147252729: 147252729
3 CHD1L NM_004284.6(CHD1L): c.234C> T (p.Thr78=) single nucleotide variant Uncertain significance GRCh37 Chromosome 1, 146724384: 146724384
Sources

Expression for Urinary System Disease

About this section
Search GEO for disease gene expression data for Urinary System Disease.
Sources

Pathways for Urinary System Disease

About this section

Pathways related to Urinary System Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Primary Focal Segmental Glomerulosclerosis FSGS 1
10.67 NPHS1 NPHS2 WT1
2
Overview of nanoparticle effects 1
10.43 CRP FN1
3
Osteoblast Signaling 1
10.1 FGF23 PTH
Sources

GO Terms for Urinary System Disease

About this section

Cellular components related to Urinary System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.9 ACE ALB B2M CST3 FN1 HIST2H2AA3
2 extracellular region GO:0005576 9.73 ACE ALB B2M CRP CST3 EPO
3 endoplasmic reticulum lumen GO:0005788 9.65 ALB B2M CST3 FGF23 FN1
4 extracellular space GO:0005615 9.36 ACE ALB B2M CRP CST3 EPO
5 slit diaphragm GO:0036057 9.32 NPHS1 NPHS2

Biological processes related to Urinary System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 amyloid-beta metabolic process GO:0050435 9.46 ACE REN
2 angiotensin maturation GO:0002003 9.43 ACE REN
3 acute-phase response GO:0006953 9.43 CRP EPO FN1
4 glomerular basement membrane development GO:0032836 9.4 NPHS1 WT1
5 metanephric mesenchyme development GO:0072075 9.37 SIX1 WT1
6 excretion GO:0007588 9.33 NPHS1 NPHS2 UMOD
7 phosphate ion homeostasis GO:0055062 9.32 FGF23 PTH
8 kidney development GO:0001822 9.26 ACE REN SIX1 WT1
9 cellular protein metabolic process GO:0044267 9.1 ALB B2M CST3 FGF23 FN1 KLK3

Molecular functions related to Urinary System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endopeptidase activity GO:0004175 8.8 ACE KLK3 REN
Sources

Sources for Urinary System Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....